Evidence map›Paper›PMID 25132642›Full record

ArticleArchives of biochemistry and biophysics2014

Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.

Jonathan G Bonchak, Jonathan M Eby, Kristin A Willenborg, David Chrobak, Steven W Henning, Anna Krzywiec, Steven L Johnson, I Caroline Le Poole

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of biochemistry and biophysics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jonathan G BonchakDepartments of Medicine and Radiology, Loyola University Medical Center, Maywood, IL, USA.
Jonathan M EbyOncology Research Institute, Loyola University Medical Center, Maywood, IL, USA.
Kristin A WillenborgOncology Research Institute, Loyola University Medical Center, Maywood, IL, USA.
David ChrobakOncology Research Institute, Loyola University Medical Center, Maywood, IL, USA.
Steven W HenningOncology Research Institute, Loyola University Medical Center, Maywood, IL, USA.
Anna KrzywiecIllinois Mathematics and Science Academy, Aurora, IL, USA.
Steven L JohnsonDepartment of Genetics, Washington University School of Medicine, St. Louis, MA, USA.
I Caroline Le PooleOncology Research Institute, Loyola University Medical Center, Maywood, IL, USA; Departments of Pathology, Microbiology and Immunology, Loyola University Medical Center, Maywood, IL, USA. Electronic address: ilepool@luc.edu.
Loyola University Medical Center · USIllinois Mathematics and Science Academy · USWashington University in St. Louis · US

Funding

REGULATION OF ADULT STEM CELLS IN ZEBRAFISHR01GM056988 · NIGMS · WASHINGTON UNIVERSITY · PI JOHNSON, STEPHEN L · 1998 to 2016
$6.0M
Chemopreventive treatment of familial melanomaR03CA128068 · NCI · LOYOLA UNIVERSITY CHICAGO · PI LE POOLE, I. CAROLINE · 2007 to 2008
$149k
NCI NIH HHS R03 CA128068NIGMS NIH HHS R01 GM056988
6 · The paper itself

Abstract

Monobenzyl ether of hydroquinone (MBEH) is cytotoxic towards melanocytes. Its treatment efficacy is limited by an inability to eradicate stem cells. By contrast, 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-DPAT) affects melanocyte stem cell survival. MBEH and 8-DPAT were added to melanocytes and melanoma cells to compare cytotoxicity. Stem cell content among viable cells was determined by fluorocytometry using markers CD34, Pax3, and CD271. Immunostaining was used to identify stem cells in skin explants treated with MBEH or 8-DPAT ex vivo. Mice were exposed to MBEH or 8-DPAT and scanned for depigmentation before harvesting skin. MBEH exposure prompted a relative increase in stem cells among cultured melanocytes and melanoma cells, as treatment preferentially eliminated differentiated cells and spared the stem cells. Viability of this remaining, enriched stem cell population was however rapidly reduced by exposure to 8-DPAT within melanocyte and melanoma cell cultures. In human skin explants, the abundance of melanocyte stem cells was also visibly reduced after 8-DPAT treatment, in contrast to tissue exposed to MBEH. Meanwhile, significant depigmentation of the mouse pelage and loss of differentiated melanocytes was observed in vivo in response to topical application of MBEH, but not 8-DPAT. Prolonged application of the latter agent instead appeared to effectively reduce the abundance of melanocyte stem cells in the dermis. This furthers the idea that MBEH and 8-DPAT target complementary cell populations. Results indicate that combination treatment may demonstrate superior therapeutic activity by eliminating both differentiated and tumor initiating populations.

Indexed as

8-Hydroxy-2-(di-n-propylamino)tetralinAdministration, TopicalAnimalsCell DifferentiationCells, CulturedCell SurvivalDrug SynergismHumansHydroquinonesMelanocytesMelanomaMiceMice, Inbred C57BLNeoplastic Stem CellsSkin Lightening PreparationsSkin Pigmentation8-Hydroxy-2-(di-n-propylamino)tetralinHydroquinonesmonobenzoneSkin Lightening Preparations8-DPATMBEHMelanocyteMelanomaPigmentationStem cellsViability

Identifiers

PMID25132642
PMCPMC4221435
OpenAlexW2013795422

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.